ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Non-Profit Spent $1.3 Million On Consultants.

March 28, 2008

Tykerb Plus Herceptin Better Than Monotherapy, Study Says

December 25, 2009

Evidence Too Weak to Link Agent Orange, Cancer, IOM Says

March 22, 2002

In Brief: Judith Salerno Named President and CEO of Komen

June 21, 2013

Vogel To Succeed Yates As VP for Research At American Cancer Society.

October 17, 2008

ASTRO Issues Statement On APBI For Breast Cancer

August 28, 2009